Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives

Area of Science:

• Oncology
• Immunology
• Cell Therapy

Background:

• Advanced digestive tract cancers lack curative systemic treatments.
• Adoptive T-cell immunotherapy involves modifying and re-infusing T lymphocytes.
• Previous trials explored various T-cell types with mixed results.

Purpose of the Study:

• To review completed and ongoing clinical trials of adoptive T-cell immunotherapy for digestive tract cancers.
• To focus on current challenges and future strategies for enhancing treatment efficacy.
• To assess the safety and antitumor potential of T-cell transfer strategies.

Main Methods:

• Review of clinical trials investigating non-engineered T cells (e.g., TILs, NK cells) and engineered T cells (e.g., CAR-T, TCR-T).
• Analysis of studies assessing safety and efficacy in metastatic and adjuvant settings.
• Examination of obstacles and future directions in T-cell immunotherapy.

Main Results:

• Variable success observed in past T-cell immunotherapy trials for digestive cancers.
• Majority of completed trials focused on safety assessment.
• New trials are designed to formally evaluate antitumor potential.

Conclusions:

• Adoptive T-cell immunotherapy is a developing treatment for digestive tract cancers.
• Overcoming current obstacles is crucial for maximizing therapeutic success.
• Future research will focus on optimizing T-cell strategies for better patient outcomes.